Shire PLC (NASDAQ:SHPG) – Stock analysts at Jefferies Group lowered their FY2018 earnings per share estimates for shares of Shire in a report issued on Thursday. Jefferies Group analyst D. Steinberg now expects that the biopharmaceutical company will earn $15.23 per share for the year, down from their previous forecast of $16.25. Jefferies Group also issued estimates for Shire’s Q4 2018 earnings at $3.78 EPS and FY2019 earnings at $16.48 EPS.
Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.86 by $0.12. The business had revenue of $4.14 billion during the quarter. Shire had a net margin of 28.17% and a return on equity of 14.75%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.37 EPS.
A number of other analysts also recently issued reports on the stock. JPMorgan Chase & Co. restated a “neutral” rating on shares of Shire in a report on Tuesday. Royal Bank of Canada cut their price target on shares of Shire to $181.00 and set an “outperform” rating for the company in a report on Friday. B. Riley cut their price target on shares of Shire from $201.00 to $181.00 and set a “buy” rating for the company in a report on Friday. Cantor Fitzgerald set a $222.00 price target on shares of Shire and gave the stock a “buy” rating in a report on Wednesday, February 14th. Finally, Sanford C. Bernstein upgraded shares of Shire from a “market perform” rating to an “outperform” rating in a report on Wednesday, February 14th. One analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. Shire has an average rating of “Buy” and a consensus price target of $205.00.
Shares of Shire (NASDAQ:SHPG) traded down $1.24 during midday trading on Monday, hitting $134.06. 944,300 shares of the stock were exchanged, compared to its average volume of 1,464,015. The firm has a market cap of $40,337.85, a P/E ratio of 9.13, a P/E/G ratio of 0.75 and a beta of 1.41. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. Shire has a fifty-two week low of $123.73 and a fifty-two week high of $192.15.
Large investors have recently bought and sold shares of the stock. SeaCrest Wealth Management LLC purchased a new position in shares of Shire during the 4th quarter worth approximately $107,000. Amica Retiree Medical Trust purchased a new position in Shire in the 4th quarter valued at approximately $120,000. BB&T Investment Services Inc. boosted its position in Shire by 1,672.3% in the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 786 shares during the period. Avestar Capital LLC purchased a new position in Shire in the 4th quarter valued at approximately $116,000. Finally, Steward Partners Investment Advisory LLC purchased a new position in Shire in the 3rd quarter valued at approximately $159,000. 20.92% of the stock is owned by hedge funds and other institutional investors.
The business also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Investors of record on Friday, March 9th will be given a dividend of $0.8937 per share. The ex-dividend date is Thursday, March 8th. This represents a dividend yield of 1.33%. This is a boost from Shire’s previous semiannual dividend of $0.15. Shire’s dividend payout ratio (DPR) is presently 6.55%.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.